Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Retained Earnings: 2021-2025

Historic Retained Earnings for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to -$476.3 million.

  • Kiniksa Pharmaceuticals International's Retained Earnings rose 7.01% to -$476.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$476.3 million, marking a year-over-year increase of 7.01%. This contributed to the annual value of -$521.1 million for FY2024, which is 9.04% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Retained Earnings is -$476.3 million, which was up 3.73% from -$494.8 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Retained Earnings peaked at -$476.3 million during Q3 2025, and registered a low of -$720.6 million during Q2 2022.
  • Moreover, its 3-year median value for Retained Earnings was -$499.6 million (2024), whereas its average is -$498.8 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first fell by 23.57% in 2022, then spiked by 32.09% in 2023.
  • Kiniksa Pharmaceuticals International's Retained Earnings (Quarterly) stood at -$675.4 million in 2021, then increased by 27.15% to -$492.0 million in 2022, then grew by 2.86% to -$477.9 million in 2023, then declined by 9.04% to -$521.1 million in 2024, then increased by 7.01% to -$476.3 million in 2025.
  • Its Retained Earnings stands at -$476.3 million for Q3 2025, versus -$494.8 million for Q2 2025 and -$512.6 million for Q1 2025.